Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Curr Opin Cardiol. 2020 May;35(3):207-218. doi: 10.1097/HCO.0000000000000720.
This review aims to highlight the association between gut microbiome and cardiovascular disease (CVD) with emphasis on the possible molecular mechanisms by which how gut microbiome contributes to CVD.
Increasingly, the roles of gut microbiome in cardiovascular health and disease have gained much attention. Most of the investigations focus on how the gut dysbiosis contributes to CVD risk factors and which gut microbial-derived metabolites mediate such effects.
In this review, we discuss the molecular mechanisms of gut microbiome contributing to CVD, which include gut microbes translocalization to aortic artery because of gut barrier defect to initiate inflammation and microbial-derived metabolites inducing inflammation-signaling pathway and renal insufficiency. Specifically, we categorize beneficial and deleterious microbial-derived metabolites in cardiovascular health. We also summarize recent findings in the gut microbiome modulation of drug efficacy in treatment of CVD and the microbiome mechanisms by which how physical exercise ameliorates cardiovascular health. Gut microbiome has become an essential component of cardiovascular research and a crucial consideration factor in cardiovascular health and disease.
本综述旨在强调肠道微生物组与心血管疾病 (CVD) 之间的关联,并重点介绍肠道微生物组如何促进 CVD 的可能分子机制。
越来越多的证据表明肠道微生物组在心血管健康和疾病中的作用受到了广泛关注。大多数研究集中于肠道失调如何导致 CVD 风险因素,以及哪些肠道微生物衍生的代谢物介导这些影响。
在这篇综述中,我们讨论了肠道微生物组导致 CVD 的分子机制,包括由于肠道屏障缺陷导致肠道微生物易位到主动脉从而引发炎症,以及微生物衍生的代谢物诱导炎症信号通路和肾功能不全。具体而言,我们将有益和有害的微生物衍生代谢物在心血管健康方面进行了分类。我们还总结了肠道微生物组对 CVD 治疗药物疗效的调节以及运动改善心血管健康的微生物组机制的最新发现。肠道微生物组已成为心血管研究的重要组成部分,也是心血管健康和疾病的关键考虑因素。